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Effect of Darbepoetin Alfa on Exercise Tolerance in
Anemic Patients With Symptomatic Chronic Heart Failure
A Randomized, Double-Blind, Placebo-Controlled Trial
Piotr Ponikowski, MD, PHD,* Stefan D. Anker, MD, PHD,†‡ Joanna Szachniewicz, MD,*
Darlington Okonko, BSC, MRCP,† Mark Ledwidge, PHD,§ Robert Zymlinski, MD,*
Enda Ryan, MRCP,§ Scott M. Wasserman, MD, Nigel Baker, MSC, Dylan Rosser, BSC,
Stuart D. Rosen, MD,† Philip A. Poole-Wilson, MD,† Waldemar Banasiak, MD, PHD,*
Andrew J. S. Coats, DM,¶ Ken McDonald, MD§
Wroclaw, Poland; London and Cambridge, England; Berlin, Germany; Dublin, Ireland; and Sydney, Australia
Objectives This study sought to investigate whether darbepoetin alfa, an erythropoiesis-stimulating protein (ESP), improves
exercise capacity in patients with symptomatic chronic heart failure (CHF) and anemia.
Background Anemia is common in patients with CHF.
Methods In a multicenter, randomized, double-blind, placebo-controlled study, CHF patients with anemia (hemoglobin
9.0 to 12.0 g/dl) received subcutaneous placebo (n  22) or darbepoetin alfa (n  19) at a starting dose of
0.75 g/kg every 2 weeks for 26 weeks. The primary end point was change in exercise tolerance from baseline
to week 27 as measured by peak oxygen uptake (ml/min/kg body weight). Other end points included changes
in absolute peak VO2 (ml/min), exercise duration, and health-related quality of life.
Results Differences (95% confidence interval) in mean changes from baseline to week 27 between treatment groups were
1.5 g/dl (0.5 to 2.4) for hemoglobin concentration (p 0.005), 0.5 ml/kg/min (0.7 to 1.7) for peak VO2 (p  0.40),
45 ml/min (35 to 127) for absolute peak VO2 (p  0.27), and 108 s (11 to 228) for exercise duration (p
0.075). Patients receiving darbepoetin alfa compared with placebo had an improvement in self-reported Patient’s
Global Assessment of Change (79% vs. 41%, p 0.01) but no significant differences in the Kansas City Cardiomyop-
athy and Minnesota Living with Heart Failure Questionnaire scores. Darbepoetin alfa was well tolerated.
Conclusions In patients with symptomatic CHF and anemia, darbepoetin alfa increased and maintained hemoglobin concentra-
tions and improved health-related quality of life. A trend toward increased exercise time but not peak VO2 was ob-
served. (Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptom-
atic Congestive Heart Failure (CHF) and Anemia; http://clinicaltrials.gov/ct/show/NCT00117234?order 1;
NCT00117234). (J Am Coll Cardiol 2007;49:753–62) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.024s
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Anemia is recognized as a common comorbid-
ity in patients with chronic heart failure (CHF)
(1–3). Initial data from a recent, large observa-
tional study of patients with CHF attending
cardiology clinics showed that 33% had a he-
moglobin concentration12.0 g/dl (4). Several
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ssociated with an increase in left ventricular mass (2), a
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Darbepoetin Alfa in Heart Failure February 20, 2007:753–62tality (2,5–8). Recently, a small
number of preliminary studies
have reported that correction of
low hemoglobin concentrations
using erythropoiesis-stimulating
proteins (ESPs) may improve
cardiac and renal function and
reduce the need for hospitaliza-
tion and diuretics in patients
with severe HF (9,10).
Another consequence of ane-
mia in CHF is reduced exercise
tolerance and poor health-related
quality of life (1,11,12). One
small, single-center, randomized,
single-blinded study has sug-
gested that treatment of anemic
CHF patients with an ESP may
improve measures of exercise tol-
erance, such as peak VO2 and
exercise duration, as well as
health-related quality of life (13).
To date, no study has investi-
ated these end points in a larger randomized, double-blind,
lacebo-controlled trial.
We report here the results of a randomized, double-blind,
lacebo-controlled study that determined the effect of treat-
ent with subcutaneous darbepoetin alfa, a long-acting
SP that stimulates erythropoiesis in the same manner as
ndogenous erythropoietin (14), on exercise tolerance as
easured by changes in peak VO2, absolute peak VO2, and
xercise duration in patients with symptomatic CHF and
nemia. Other end points included safety, health-related
uality of life, functional status (New York Heart Associa-
ion [NYHA] functional class), brain natriuretic peptide
BNP) concentration, body weight, and on-study
ospitalization.
ethods
atients. Individual institutional review committees ap-
roved the study, and all patients gave written informed
onsent before any study-specific procedures were per-
ormed. The main inclusion criteria were: age 21 years;
ymptomatic CHF with exercise limitation on the treadmill;
eproducible peak VO2 16 ml/kg/min during screening
btained from at least 2 and up to 5 exercise tests at separate
isits, with results from the last completed test within
5% of the previous one; hemoglobin concentration 9.0
o 12.0 g/dl; left ventricular ejection fraction (LVEF)
40%; receiving stable, recommended therapy for CHF
angiotensin-converting enzyme inhibitor or angiotensin
eceptor blocker, and a beta-blocker if tolerated); not likely
o receive cardiac transplantation within 6 months after
andomization; being iron replete (transferrin saturation
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide concentration
CHF  chronic heart failure
CI  confidence interval
ESP  erythropoiesis-
stimulating protein
KCCQ  Kansas City
Cardiomyopathy
Questionnaire
LVEF  left ventricular
ejection fraction
MLHFQ  Minnesota Living
With Heart Failure
Questionnaire
NYHA  New York Heart
Association
PGA  Patient’s Global
Assessment of Change
VO2  oxygen uptake per
kilogram body weight15%); resting blood pressure 160/100 mm Hg; anderum creatinine3.0 mg/dl. Patients were excluded if they
eceived blood transfusions or ESP within 12 weeks of
andomization or were receiving any other investigational
rugs.
tudy design. This was a phase 2, randomized, double-
lind, placebo-controlled study conducted in 3 centers (Fig.
). Patients were randomly assigned in a 1:1 ratio to receive
ither subcutaneous placebo or darbepoetin alfa at a starting
ose of 0.75 g/kg every 2 weeks for 26 weeks. Darbepoetin
lfa (Aranesp, Amgen, Inc., Thousand Oaks, California)
as provided in single-dose vials (200 g/ml). Placebo was
upplied in identical single-dose vials. Randomization was
ithin the study centers in blocks of 2 and 4, and without
urther stratification. The randomization sequence, which
as computer-generated and held by an independent stat-
stician, was implemented via a central randomization co-
rdinator and was concealed from investigators throughout
Figure 1 Summary of Study Design and Procedures
Hb  hemoglobin; HRQOL  health-related quality of life;
NYHA  New York Heart Association.
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February 20, 2007:753–62 Darbepoetin Alfa in Heart Failurehe study. Patients and personnel at the study centers were
linded to the identity of the study drug, hematology results
except at baseline), and hormone markers. The central
andomization coordinator calculated the dose in g/kg and
he volume of drug to be administered, providing only
nformation on the volume.
Hemoglobin concentration was monitored weekly, with
entral data assessment at the core laboratory. During the
itration phase, darbepoetin alfa doses were titrated by
25% of the current dose to maintain a gradual hemoglobin
oncentration increase of 0.5 g/dl but 1.5 g/dl every 3
eeks. When hemoglobin was 13.0 g/dl and had in-
reased by at least 2.0 g/dl from baseline, the dose was
educed by 25% from the current dose. During the main-
enance phase, the dose was adjusted by 25% to maintain
he hemoglobin concentration at the target of 13.0 to 15.0
/dl. If hemoglobin was 15.5 g/dl, study drug was
ithheld; dosing resumed at the previous schedule and at
5% of the most recent dose after at least 2 weeks had
assed and once the hemoglobin concentration was 14.0
/dl. To maintain the study blind, volume changes of
lacebo were implemented to mimic the dose changes in the
arbepoetin alfa group. All patients were prescribed 200 to
00 mg/day of elemental oral iron, unless baseline serum
erritin was 800 ng/ml. The treatment phase lasted for 26
eeks, and patients underwent a safety follow-up examina-
ion 4 weeks after receiving the final dose of study drug.
nd points. The primary end point was the change from
aseline to week 27 in exercise tolerance, as measured by
eak VO2 adjusted for body weight (ml/kg/min). The study
as designed to have approximately 80% power to detect a
ifference of 1.1 ml/kg/min between treatment groups in
ean change in peak VO2 from baseline to week 27,
ssuming SD of 1.3 ml/kg/min and a significance level of
.05. This effect was estimated using data from a previous
linical study (13), and was chosen on the basis of clinical
elevance.
Other end points included changes from baseline to week
7 in absolute peak VO2 (ml/min), exercise duration (in
econds), hemoglobin, NYHA functional classification,
ealth-related quality of life, BNP, body weight, and
n-study hospitalizations. Health-related quality of life was
ssessed using 2 different disease-specific instruments, the
ansas City Cardiomyopathy Questionnaire (KCCQ) (15)
nd the Minnesota Living With Heart Failure Question-
aire (MLHFQ) (16), as well as a brief generic instrument,
he Patient’s Global Assessment of Change (PGA) (17).
afety end points were the incidence of adverse events,
hanges in laboratory measurements and vital signs, and
eroreactivity to ESPs.
ardiopulmonary exercise testing. Exercise testing was
arried out on a treadmill using a modified Naughton
rotocol (18). Measurements of oxygen uptake, carbon
ioxide production, and minute ventilation were taken
reath-by-breath and averaged over 15-s intervals. Peak O2
ptake was measured as an average of the last 15 s of exercise. Maximal exercise capacity was attained if the
espiratory exchange ratio was 1.00 and had increased by
t least 0.15 from the resting value.
tatistical analysis. All data were analyzed according to
he intent-to-treat principle. Imputations were made using
he last-observation-carried-forward method. Pre-specified
ensitivity analyses to evaluate the impact of missing data
ere also performed for the primary end point, including a
epeated measures analysis of covariance model, and an
nalysis based on the completer set (subjects who completed
7 weeks of treatment). These analyses included baseline
eak VO2 and study center as covariates. The results from
hese sensitivity analyses were similar to the results from the
rimary analysis with last value carried forward imputation.
or the primary analysis, an analysis of covariance model
as used, with treatment as the main effect and baseline
eak VO2 and study center as covariates. Other statistical
nalyses included summary statistics (point estimates of
eek-27 peak VO2 and change from baseline to week 27 for
ach treatment group); estimates and 2-sided 95% confi-
ence intervals (95% CI) for the difference between least-
quares means of the 2 treatment groups, adjusted for the
ffects of center and baseline values of the variable being
nalyzed. Results were considered to be statistically signif-
cant if p  0.05. Health-related quality of life domain
cores were computed using published scoring guidelines
15,19). All analyses were carried out using SAS software
ersion 8.2 (SAS Institute Inc., Cary, North Carolina).
esults
tudy cohort. Of 93 CHF patients screened, 52 (56%)
ere excluded from the study. The main reasons were
VEF 40% (n  16), hemoglobin concentration not
ithin specified range (n  16), and peak VO2 16
l/kg/min (n  10). Forty-one patients were randomly
ssigned to receive either darbepoetin alfa (n  19) or
lacebo (n 22). No patients withdrew before receiving the
tudy drug, but 3 patients (16%) in the darbepoetin alfa
roup (adverse event, n 2; withdrawn consent, n 1) and
(14%) in the placebo group (death, n  1; withdrawn
onsent, n  1; protocol-specified criteria, n  1) discon-
inued the study early.
Treatment groups were generally balanced with respect to
emographics and baseline characteristics (Tables 1 and 2).
he characteristics of patients enrolled at separate centers
id not affect the study results. There were some differences
n hemoglobin values determined by the core laboratory and
y the investigative sites, respectively. Consequently, 17
atients (41%) were recruited with hemoglobin concentra-
ions 12.0 g/dl (n  10 in the darbepoetin alfa and n  6
n the placebo group, with hemoglobin 12.0 to 13.0 g/dl;
 0 in the darbepoetin alfa and n  1 in the placebo
roup, with hemoglobin 13.0 g/dl). All 17 patients met
ligibility criteria specified in the protocol because screening
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Darbepoetin Alfa in Heart Failure February 20, 2007:753–62emoglobin concentrations obtained at local laboratories
ere 12.0 g/dl.
xercise. All patients randomly assigned to treatment were
ssessed for the primary end point (imputed peak VO2 values
ere used for 8 patients, 4 in each treatment group).
xercise tolerance, as measured by the change in peak VO2
rom baseline to week 27, did not change significantly in
ither treatment group (Table 3, Fig. 2A). The mean
reatment difference was 0.5 ml/kg/min (95% CI 0.7 to
.7, p  0.40). Sensitivity analyses of pre-specified baseline
actors (e.g., gender, age, race, smoking history, beta-
atient Baseline Clinical Characteristics
Table 2 Patient Baseline Clinical Characteristics
Placebo
(n  22)
Darbepoetin Alfa
(n  19)
NYHA functional classification, n (%)
I 1 (5) 0 (0)
II 8 (36) 11 (58)
IIIa 11 (50) 5 (26)
IIIb 2 (9) 3 (16)
Uses beta-blocker, n (%) 18 (82) 15 (79)
Primary cause of CHF, n (%)
Ischemic heart disease 19 (86) 16 (84)
Dilated cardiomyopathy 3 (14) 1 (5)
Other 0 (0) 2 (11)
atient Baseline Demographicsnd Labor tory Measurements
Table 1 Patient Baseline Demographicsand Laboratory Measurements
Placebo
(n  22)
Darbepoetin
Alfa
(n  19)
All Patients
(n  41)
Men, n (%) 10 (45) 12 (63) 22 (54)
Race, n (%)
Caucasian 22 (100) 18 (95) 40 (98)
Asian 0 (0) 1 (5) 1 (2)
Age group, n (%)
75 yrs 13 (59) 15 (79) 28 (68)
75 yrs 9 (41) 4 (21) 13 (32)
Mean  SD age, yrs 72 7 70 7 71 7
Mean  SD weight, kg 72 11 73 14 72 12
Hemoglobin
concentration,* n (%)
9.0 to 11.0 g/dl 7 (32) 4 (21) 11 (27)
11.0 to 12.0 g/dl 8 (36) 5 (26) 13 (32)
12.0 g/dl 7 (32) 10 (53) 17 (41)
Absolute reticulocyte
count, 109/l
n 20 15 35
Mean  SD 101 47 91 32 97 41
Red blood cells, 1012/l
n 21 17 38
Mean  SD 4.0 0.3 4.0 0.4 4.0 0.4
Serum ferritin, g/l
n 22 19 41
Median (25th, 75th) 161 (83, 256) 71 (46, 143) 129 (47, 185)
ote that local laboratories were used for inclusion testing, but the core laboratory value was used
o calculate the dose of darbepoetin alfa administered. *As assessed by core laboratory.cHF  heart failure; NYHA  New York Heart Association.locker use, duration of CHF, and NYHA functional class)
howed no significant effect on change in exercise tolerance.
From baseline to week 27, absolute peak VO2 (mean 
E) in the darbepoetin alfa arm was 43  30 ml/min
ompared with placebo3 28 ml/min (Table 3, Fig. 2B).
he mean treatment difference in absolute peak VO2
hanges was 45 ml/min (95% CI 35 to 127, p  0.27).
Over the course of the study, exercise duration (adjusted
ean  SE) decreased by 67  63 s in the placebo group,
ompared with an increase of 42  59 s in the darbepoetin
lfa group (Table 3, Fig. 2C). The adjusted mean treatment
ifference between the 2 groups was 108 s (95% CI 11 to
28, p  0.075).
In an exploratory analysis, no significant correlation
etween change in hemoglobin concentration and change in
xercise tolerance (peak VO2 and absolute peak VO2) was
vident in either treatment group (all r 0.37, p  0.12). A
ignificant association was found between changes in hemo-
lobin concentration and changes in exercise duration in
atients receiving darbepoetin alfa, but not in the placebo
roup (r  0.64, p  0.003) (Fig. 3).
eproducibility of cardiopulmonary exercise testing and
ower calculation on the basis of the actual results. The
ithin-subject coefficients of variance for peak VO2 that
ere derived from the final 2 valid exercise tests (last
creening and baseline) ranged from 0.01% to 28% with a
ean  SE coefficient of variance of 5.2%  1.0%. When
he results were split by the 3 participating centers, they did
ot significantly vary, with the following mean (range)
ummary of Results fore oglobin and Exercise End Points
Table 3 Summary of Results forHemoglobin and Exercise End Points
Placebo
(n  22)
Darbepoetin Alfa
(n  19)
Mean  SE hemoglobin (g/dl)
Baseline 11.6 0.2 11.8 0.2
Week 27 12.3 0.4 13.9 0.4
Mean  SE change from
baseline to week 27*
0.9 0.5 2.4 0.4
Mean  SE peak VO2 (ml/kg/min)
Baseline 12.2 0.6 12.4 0.6
Week 27 11.7 0.5 12.4 0.6
Mean (95% CI) change from
baseline to week 27*
0.1 (1.2 to 1.3) 0.5 (0.6 to 1.7)
Mean  SE absolute peak VO2
(ml/min)
Baseline 876 49 892 49
Week 27 830 50 897 50
Mean (95% CI) change from
baseline to week 27*
3.0 (92 to 86) 43 (39 to 125)
Mean  SE exercise duration, s
Baseline 526 54 559 47
Week 27 468 52 597 54
Mean (95% CI) change from
baseline to week 27*
67 (195 to 62) 42 (78 to 162)
Adjusted for baseline value and study center.
CI  confidence interval; VO2  oxygen uptake.oefficients of variance: 2.1% (0.04% to 3.6%), 8.7% (0.5%
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February 20, 2007:753–62 Darbepoetin Alfa in Heart Failureo 28%) and 4.3% (0.01% to 18%). The SD of the changes
rom baseline to week 27 in peak VO2 for patients randomly
ssigned to the placebo group was 2.23 ml/kg/min (range
7.9 to 3.4 ml/kg/min), with the following SDs (ranges)
t the center: Dublin 0.69 ml/kg/min (0.1 to 1.4 ml/kg/
in), London 0.78 ml/kg/min (1.6 to 3.4 ml/kg/min),
roclaw 2.23 ml/kg/min (7.9 to 0.33 ml/kg/min). The
bserved SD for repeated assessments was larger than the
lanned SD (1.3 ml/kg/min difference), indicating high
Figure 2 Change From Baseline in Measures of Exercise Tolera
(A) Mean change in peak VO2 over time, p  0.248 for darbepoetin alfa versus pl
darbepoetin alfa versus placebo. (C) Mean change in exercise duration over time,ariability. Mecondary end point assessments. CHANGE IN HEMOGLO-
IN CONCENTRATION. During the study, an increase in
emoglobin concentrations was observed in the darbepoetin
lfa group, with little change occurring in the placebo group
Table 3, Fig. 4). At the end of the study, the change from
aseline in hemoglobin was 2.4 0.4 g/dl vs. 0.9 0.5 g/dl
or the darbepoetin alfa and placebo groups, respectively.
he difference in the mean change between the treatment
roups was 1.5 g/dl (range 0.5 to 2.4 g/dl) (p  0.005).
and Duration Over Time
(B) Mean change in total VO2 over time, p  0.134 for
.074 for darbepoetin alfa versus placebo. Data are mean  SE.nce
acebo.
p  0ean values for iron parameters were similar and either
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Darbepoetin Alfa in Heart Failure February 20, 2007:753–62n the normal range for serum iron and ferritin, or at the
ow end of the normal ranges for total iron binding
apacity and transferrin saturation, for both treatment
roups at baseline and throughout the study (data not
hown).
YHA FUNCTIONAL CLASS. In a continuous analysis of
hanges in NYHA functional class, the mean changes from
aseline to week 27 were 0.11 (range 0.30 to 0.08) and
0.09 (range 0.31 to 0.13) for the darbepoetin alfa and
Figure 3 Individual Changes From Baseline to Week 27 in Hem
Concentration Relative to the Change From Baseline
Multiple values may occur in the same location. Placebo: change in VO2  16.5 
darbepoetin alfa: change in VO2  158  change in Hb  310. Solid line  place
Figure 4 Development of Hemoglobin Concentrations Over Tim
Patients Receiving Placebo or Darbepoetin Alfa (Inten
Data are mean  SE.lacebo groups, respectively. Only 2 patients (11%) in the
arbepoetin alfa arm experienced an improvement from
aseline to week 27 of 1 NYHA functional class or more,
ompared with 6 patients (27%) in the placebo group (p 
.25).
EALTH-RELATED QUALITY OF LIFE. A significantly larger
roportion of patients receiving darbepoetin alfa reported an
mprovement at week 27 in PGA, compared with patients
eceiving placebo: 15 of 19 (79%) vs. 9 of 22 (41%) patients,
in
ercise Duration
e in Hb  74.8;
shed line  darbepoetin alfa.
Treat Analysis Set)oglob
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February 20, 2007:753–62 Darbepoetin Alfa in Heart Failureespectively (p  0.01) (Fig. 5). When health-related
uality of life was measured using the KCCQ, there were no
tatistically significant differences (Table 4) in the mean
hange from baseline to week 27 between darbepoetin alfa
nd placebo groups in either of the KCCQ individual
omain scores or the 3 summary scores (data not shown).
linically significant changes of 5 points (20,21) were
ecorded for the individual domain, and summary scores
or both the placebo and darbepoetin alfa groups (Table
Figure 5 Improvement in PGA at Week 13 and Week 27
PGA  Patient’s Global Assessment of Change.
ealth-Related Quality of Life
Table 4 Health-Related Quality of Life
Placebo
(n  22)
Darbepoetin Alfa
(n  19)
Mean  SD change from baseline to
week 27
KCCQ summary scores
Total symptom 7.6 17.5 9.1 15.7
Clinical summary 8.6 17.0 9.6 15.1
Overall summary 10.4 15.5 12.4 17.0
KCCQ individual domain scores*
Physical limitation 9.8 19.3 10.1 18.6
Symptom burden 8.3 21.5 9.3 19.2
Symptom frequency 6.9 14.1 8.9 15.4
Self efficacy 19.1 17.2 14.6 20.2
Quality of life 10.8 17.1 11.6 26.5
Social limitation 13.5 21.1 18.5 25.5
MLHFQ scores†
Total score 13.7 24.9 10.8 22.1
Physical dimension 7.9 11.5 5.0 9.5
Emotional dimension 2.4 5.8 3.6 6.1
The KCCQ symptom stability domain quantifies recent changes (over the previous 2 weeks) in
atients’ symptoms, whereas the other 6 individual KCCQ domains quantify patients’ health status
n a cross-functional fashion. Therefore, results for the symptom stability domain are reported as
ean (SD) scores at baseline and at week 27, rather than expressed as a change over time:
lacebo baseline, 59.4 (20.2) and week 27, 60.0 (28.0); darbepoetin alfa baseline, 56.9 (26.9) and
eek 27, 80.4 (22.3). †A negative change indicates an improvement in health-related quality
f life.e
KCCQ  Kansas City Cardiomyopathy Questionnaire; MLHFQ  Minnesota Living with Heart
ailure Questionnaire.). Assessment of health-related quality of life using the
LHFQ instrument showed no significant difference be-
ween the darbepoetin alfa and placebo groups in the mean
hanges from baseline to week 27 for all 3 scores. Clinically
ignificant changes of 5 points (22,23) were recorded for
he total MLHFQ score for both the placebo and darbepo-
tin alfa groups (Table 4). The magnitude of clinically
ignificant changes for the emotional and physical MLHFQ
omains is not well defined.
AFETY. Occurrences of adverse events for both treatment
roups are listed in Table 5. Fifteen (79%) and 13 (59%)
atients receiving darbepoetin alfa and placebo, respectively,
xperienced at least 1 adverse event while being treated.
wo deaths occurred during the study, 1 in each treatment
roup. The causes of death were recorded as circulatory
nsufficiency and sudden death in the darbepoetin alfa and
lacebo groups, respectively. Neither death was considered
y the investigators to be related to treatment.
Events that occurred with a 5% difference-in-incidence
ate between the treatment groups are detailed in Table 5.
hose that were more common in the darbepoetin alfa
roup vs. placebo were neurologic signs and symptoms not
lsewhere classifiable, upper respiratory tract infections, and
oint-related signs. The incidences of all other adverse
dverse Events
Table 5 Adverse Events
Placebo
(n  22)
Darbepoetin Alfa
(n  19)
All adverse events, n (%) 13 (59) 15 (79)
Serious adverse events 5 (23) 4 (21)
Life-threatening adverse events 2 (9) 1 (5)
Deaths 1 (5) 1 (5)
Events with a 5% difference in incidence
between treatment groups, n (%)
Neurologic signs and symptoms NEC 1 (5) 4 (21)
Upper respiratory tract infections 0 (0) 3 (16)
Coughing and associated symptoms 4 (18) 2 (11)
Joint-related signs and symptoms 0 (0) 2 (11)
Musculoskeletal and connective tissue
signs and symptoms NEC
4 (18) 2 (11)
Appetite disorders 2 (9) 0 (0)
Breathing abnormalities 4 (18) 0 (0)
Gastrointestinal atonic and hypomotility
disorders NEC
2 (9) 0 (0)
Ischemic coronary artery disorders 2 (9) 0 (0)
Nausea and vomiting symptoms 5 (23) 0 (0)
Physical examination procedures 2 (9) 0 (0)
Adverse events of special interest, n (%) 3 (14) 3 (16)
Hypertension 0 (0) 1 (5)
Deep vein thrombosis 0 (0) 0 (0)
Pulmonary emboli 0 (0) 0 (0)
Congestive heart failure 2 (9) 1 (5)
Cerebrovascular disorder 0 (0) 1 (5)
Myocardial infarction 1 (5) 0 (0)
Seizure 0 (0) 0 (0)
EC  not elsewhere classifiable.vents were similar for the 2 treatment groups. One adverse
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Darbepoetin Alfa in Heart Failure February 20, 2007:753–62vent (neurologic signs and symptoms not elsewhere classi-
able) in the darbepoetin alfa group was considered to be
elated to treatment by the investigators. Six patients (n 
[16%] in the darbepoetin alfa and n  3 [14%] in the
lacebo group) experienced at least 1 of the 7 adverse events
onsidered to be of specific interest in patients receiving
SPs (Table 5). No occurrences of deep vein thrombosis,
ulmonary embolus, or seizure were reported during the
tudy. With the exception of 1 episode of hypertension
ecorded in the darbepoetin alfa group, blood pressure
emained stable throughout the study. No clinically relevant
hanges occurred in clinical chemistry, hematology, or vital
igns. No anti-darbepoetin alfa antibodies were detected
data not shown).
ther measures. BNP. Mean  SD baseline serum con-
entrations for BNP were 418.8 269.4 and 498.3 787.6
g/ml for the darbepoetin alfa and placebo groups, respec-
ively. The mean changes from baseline to week 27 were not
ignificantly different between the 2 treatment groups:
90.5 pg/ml (range 196.8 to 15.8 pg/ml) and 26.5
g/ml (range 121.0 to 68.0 pg/ml) for darbepoetin alfa
nd placebo, respectively. The mean treatment difference
etween the groups was –64.0 pg/ml (95% CI 192.7 to
4.7 pg/ml, p  0.32).
ODY WEIGHT. The study results suggested a possible
reservation of body weight in patients receiving darbepo-
tin alfa (mean  SE change from baseline to week 27,
0.1  1.0 kg, compared with 1.2  0.9 kg in the
lacebo group). The mean difference between the treatment
roups was not statistically significant (1.3 kg, 95% CI
1.3 to 3.9 kg, p  0.33).
OSPITALIZATION. Fewer patients were hospitalized in the
arbepoetin alfa arm than in the placebo arm. Specifically, 4
21%) and 9 (41%) patients in the darbepoetin alfa and
lacebo group, respectively, required hospitalization for any
eason (p  0.20), whereas the proportion of patients who
ere hospitalized for any CHF-related reason was 11% and
4%, respectively (p  1.0).
ERUM CREATININE, ESTIMATED GLOMERULAR FILTRA-
ION RATE, AND TRANSFERRIN SATURATION. At baseline
nd after 27 weeks, the mean serum creatinine concentra-
ions (in mg/dl) were 1.45 (SD 0.53) and 1.43 (SD 0.42) for
lacebo and 1.32 (SD 0.48) and 1.24 (SD 0.40) for drug.
he estimated glomerular filtration rates (ml/min/1.73 m2)
ere 52 (SD 25) and 49 (SD 22) for placebo and 59 (SD 23)
nd 61 (SD 20) for drug. The (%) were 34.6 (SD 12.8) and
7.7 (SD 8.9) for placebo and 25.3 (SD 6.6) and 32.1 (SD
3.3) for drug.
iscussion
his report describes the first randomized, double-blind,
lacebo-controlled study to evaluate whether therapy with
arbepoetin alfa improves exercise tolerance in patients with
ymptomatic CHF and anemia. The results show that Carbepoetin alfa treatment significantly increased hemoglo-
in concentrations and resulted in improvement in 1 mea-
ure of health-related quality of life as determined by PGA.
e could not show a statistically significant increase in
xercise tolerance as measured by either peak VO2 adjusted
or body weight or absolute peak VO2, but there was a trend
or an increase in exercise duration. In patients treated with
arbepoetin alfa, a statistically significant association existed
etween changes in hemoglobin and changes in exercise
uration. Therapy with darbepoetin alfa was well tolerated
nd showed an adverse event profile similar to that of
lacebo.
Anemia is a common comorbidity in CHF, increasing in
revalence in the more advanced stages of the disease (2).
he etiology of anemia in patients with CHF is not
ompletely understood, but is associated with many of the
ematologic features of anemia of chronic disease (24). In
HF patients, anemia is independently associated with
ncreased rates of hospital admissions and poor survival
1–3,6), but little is known about the impact of treating
nemia in these patients. Initial studies using ESPs have
hown improved cardiac function, functional capacity,
ealth-related quality of life, and exercise tolerance (10,13).
ecause of study limitations such as small sample size and
ack of double-blind and/or placebo-controlled design, no
efinitive conclusions could be drawn. It has been reported
lsewhere (25) that a certain proportion of CHF patients
ith anemia adjust their hemoglobin concentrations over
ime. Over the 26-week treatment period analyzed in the study
resented, none of the CHF patients spontaneously had
orrected anemia, and there was no significant increase in
emoglobin concentrations in patients treated with placebo.
When interpreting the results of the exercise testing
onducted in this study, several issues need to be considered.
he reproducibility of the exercise tests performed at
aseline was excellent (mean coefficient of variance 5.7%).
owever, the SD of the change from baseline to week 27 in
eak VO2 for subjects randomly assigned to placebo (2.2
l/kg/min) exceeded the expected value as used in the
riginal power calculation (1.3 ml/kg/min). The preserva-
ion and loss of weight seen in the darbepoetin alfa and
lacebo groups, respectively, may have contributed to this.
hus, the variability of the data may have had an impact on
he study’s ability to detect the desired treatment effect of
.1 ml/min/kg. In a sensitivity analysis, the exercise test
races were reviewed by a single blinded physician
A.J.S.C.), and the differences between the 2 treatment
roups were 0.38 ml/kg/min for peak VO2 (p 0.55) and 44
l/min for absolute peak VO2 (p  0.32). Our findings
nderpin some of the difficulties inherent in conducting a
ulticenter clinical study on cardiovascular exercise physiology.
These observations may in part explain the apparent
iscrepancy between our data and those reported by Man-
ini et al. (13), who conducted a preliminary exercise study
n the treatment of anemia with ESPs in symptomatic
HF patients. In their single-center study, the investigators
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February 20, 2007:753–62 Darbepoetin Alfa in Heart Failureeported a significant increase in mean SD peak VO2 from
1.0  1.8 ml/kg/min to 12.7  2.8 ml/kg/min in anemic
HF patients receiving recombinant human erythropoietin.
he study was single-blinded and enrolled fewer patients
ho had more severe CHF (NYHA functional class III and
V) and lower mean baseline peak VO2 values. The change
n hemoglobin concentrations after ESP treatment was
reater in the study by Mancini et al. (mean  SD 11.0 
.6 g/dl at baseline and 14.3  1.2 g/dl at the end of
reatment), and the results from 3 patients who did not
omplete the study were not included in the analysis.
In the double-blind, placebo-controlled, MIRACLE
Multicenter InSync Randomized Clinical Evaluation)
tudy, cardiac resynchronization resulted in a median in-
rease in peak VO2 that was 0.9 ml/kg/min greater than in
he placebo group (p  0.009), and in a median increase in
xercise duration that was 62 s greater than placebo (p 
.001) (26). In comparison, we observed a 0.5-ml/kg/min
ifference in peak VO2 between the placebo and darbepoetin
lfa groups (p  0.40) and an increase in exercise duration
rom baseline with darbepoetin alfa treatment that was 108 s
reater than with placebo (p  0.075). As such, the
mprovements in exercise duration, albeit not statistically
ignificant, observed in our study were of similar or greater
agnitude than those reported in the MIRACLE study,
hich recruited 369 patients to show a significant change.
In the present study, more patients in the darbepoetin alfa
han in the placebo group experienced improvement in
ealth-related quality of life as assessed by PGA (79% vs.
1%, p  0.01), a simple measure that has been used
reviously in cardiovascular trials (13,17). This result con-
rms data presented by Mancini et al. (13). Their study also
escribed a clinically significant improvement in MLHFQ
core from baseline to end of therapy in patients treated
ith an ESP (compared with a deterioration in MLHFQ
core in the placebo group). No formal comparison of the 2
reatment groups was made. We observed clinically signif-
cant changes from baseline to week 27 for all KCCQ
omain scores and the total MLHFQ score in darbepoetin
lfa-treated patients, but there were no significant differ-
nces in score changes between treatment groups. This may
e attributed, at least in part, to the large placebo effect
bserved with both health-related quality-of-life instru-
ents. The MLHFQ has been used extensively and has
een validated in the CHF population (19,27), but has not
hown consistently a clear discrimination between different
everities of CHF or between active treatment and placebo
28). The KCCQ is a recently developed and validated
HF-specific instrument that has been shown to be reliable
nd more sensitive to clinical change than either the
LHFQ or the Short-Form 36 (15). Although the parallel
dministration of the MLHFQ and the KCCQ in this
tudy could have provided the basis for a sensitivity com-
arison of the 2 instruments, no conclusions could be drawn
ecause of the notable effects recorded in both placebo
roups. Confounding of quality-of-life data by definitemprovements in patients receiving placebo has been de-
cribed in other interventional CHF trials (29).
tudy limitations. The study is limited by its relatively
mall sample size. The multicenter design is likely to have
ncreased the data variability compared with a single-center
tudy. Some patients were recruited with relatively higher
han required hemoglobin concentrations, which possibly
mpacted potential treatment benefits. We speculate that
he supportive therapeutic environment created by the
requently scheduled visits with health care providers during
he course of the study may have significantly contributed to
he health-related quality-of-life improvements observed in
atients receiving placebo.
onclusions. Treatment with darbepoetin alfa in patients
ith symptomatic CHF and anemia significantly increased
emoglobin concentrations and was well tolerated. A trend
oward improved exercise duration was observed, and the
ncrease in exercise time correlated with the increase in
emoglobin. Darbepoetin alfa did not result in significant
hanges in peak VO2, absolute peak VO2, or NYHA func-
ional class. Health-related quality of life as assessed by
GA was improved. The adverse event profile was similar in
he darbepoetin alfa and placebo treatment groups. These
esults support the conduct of larger trials investigating the
afety and potential benefit of treatment of anemia with
arbepoetin alfa in anemic patients with symptomatic CHF.
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